This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in Store for Radiant Logistics (RLGT) in Q1 Earnings?
by Zacks Equity Research
While a sluggish freight scenario is likely to affect Radiant Logistics' (RLGT) Q1 results, its higher revenues at the U.S. segment are expected to have aided the top line.
Aurora Cannabis (ACB) Q1 Earnings on Deck: Can Things Turnaround?
by Christopher Vargas
Aurora Cannabis (ACB) is set to report its first quarter results after the closing bell Thursday, November 14th.
U.S.-China Trade Progress, Q3 Earnings Results & Buy Yeti Stock - Free Lunch
by Benjamin Rains
The latest U.S.-China trade war news that could see the world's two largest economies roll back tariffs. Q3 earnings results from the likes of Qualcomm and Square. And why Yeti is a Zacks Rank #1 (Strong Buy) stock...
Aurora Cannabis Inc. (ACB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Buy Cronos (CRON) Stock Ahead of Earnings as Bet on Marijuana Comeback?
by Benjamin Rains
Should investors think about buying some shares of Cronos (CRON) ahead of earnings, as a bet on a marijuana market comeback?
Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) closed at $3.72 in the latest trading session, marking a -1.06% move from the prior day.
4 Highly-Ranked Cheap Stocks Trading Under $10 to Buy Right Now
by Benjamin Rains
Today we highlighted 4 'cheap' stocks that are currently trading for under $10 per share that also sport a Zacks Rank #2 (Buy) or better that investors might want to consider buying right now...
What's in the Offing for Humana's (HUM) Earnings in Q3?
by Zacks Equity Research
Humana's (HUM) third-quarter results are likely to reflect rise in expenses and a negative impact from seasonality on its bottom line.
Genesis Healthcare (GEN) to Post Q3 Earnings: What to Expect
by Zacks Equity Research
Genesis Healthcare's (GEN) third-quarter results are likely to reflect weak revenues, partially offset by same store facility growth and lower expenses.
Aurora Cannabis Inc. (ACB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) expects to have gained from calcimimetics in the third quarter.
What to Expect From Tenet Healthcare's (THC) Q3 Earnings
by Zacks Equity Research
Tenet Healthcare's (THC) third-quarter results are likely to reflect weaker revenues, partially offset by higher contribution from its Conifer segment.
Aurora Cannabis Inc. (ACB) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) closed the most recent trading day at $3.61, moving +0.28% from the previous trading session.
5 Top-Ranked Cheap Stocks Trading Under $20 to Buy Right Now
by Benjamin Rains
Today we found 5 cheap stocks currently trading for under $20 per share using our Zacks Stock Screener that investors might want to buy heading into November...
Should You Buy the Dip in Marijuana ETFs Ahead of Earnings?
by Sanghamitra Saha
Hexo's downbeat results weigh on marijuana space but many key pot companies are likely to beat in November. This could provide a good entry points to pot ETFs.
What's in the Cards for Zimmer Biomet's (ZBH) Q3 Earnings?
by Zacks Equity Research
In Spine & CMF, Zimmer Biomet (ZBH) is witnessing slowdown in growth due to difficult comps.
Aurora Cannabis Inc. (ACB) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $3.69, marking a +0.27% move from the previous day.
Can Overall Growth Boost Boston Scientific (BSX) Q3 Earnings?
by Zacks Equity Research
We are once again optimistic about the IC business of Boston Scientific (BSX), which is likely to have aided the company to retain impressive global growth in Q3.
What's in the Offing for LabCorp's (LH) Earnings in Q3?
by Zacks Equity Research
LabCorp (LH) is expected to have advanced its companion diagnostics and oncology capabilities in the third quarter.
Implied Volatility Surging for Aurora Cannabis (ACB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aurora Cannabis (ACB) stock based on the movements in the options market lately.
How to Invest in Emerging Industries Like Marijuana
by Tracey Ryniec
Investors are still crazy about the pot stocks despite this year's roller coaster ride.
Aurora Cannabis Inc. (ACB) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) closed the most recent trading day at $4.15, moving +0.97% from the previous trading session.
Stocks Fall on U.S. Blacklist, China & the NBA and Buy Roku - Free Lunch
by Benjamin Rains
A look at the new U.S. blacklist on nearly 30 Chinese companies and how it might impact the upcoming trade talks. A dive into the dispute between the NBA and China, marijuana stocks, and why Roku is a Zacks Rank #1 (Strong Buy) - Free Lunch
Aurora Cannabis Inc. (ACB) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $4.15, marking a +0.73% move from the previous day.
Is Constellation Brands (STZ) Stock a Buy Heading into Q2 Earnings?
by Benjamin Rains
Should investors consider buying shares of Constellation Brands (STZ) as we head into the release of its second quarter fiscal 2020 earnings results, due out on Thursday, October 3?